Swasher Ultra Low-Lint Surgical Towels

Syntervention
(888) 853-6559
www.syntervention.com

KEY FEATURES

- 99% less lint than standard woven towels
- Excellent fluid capacity for uncompromised performance
- Lightweight to reduce medical waste
- Latex- and DEHP-free

Swasher is an ultra low-lint and low-particulate surgical towel from Syntervention (Rocky Mount, NC) designed to reduce lint and particulate contamination and minimize the transfer of foreign materials in interventional and surgical procedures. Swasher weighs less than a regular towel, with the potential to reduce the cost of medical waste disposal. It is biocompatible, latex- and DEHP-free, and available for both sterile and nonsterile applications. The product is soft and drapable, yet strong, with a "grab tab" fold for easy opening.

Lotus Valve System

Boston Scientific Corporation
(888) 272-1001
www.bostonscientific.com/LotusValve

KEY FEATURES

- Unique Adaptive Seal technology
- Controlled mechanical expansion
- Fully repositionable, redeployable, and retrievable
- Early valve operation

The Lotus valve system (Boston Scientific Corporation, Natick, MA), a transcatheter aortic valve replacement technology, recently received CE Mark approval. The Lotus valve system is a treatment alternative for patients with severe aortic stenosis at high risk with surgical valve replacement.

To provide physicians with total control during valve implantation, the Lotus valve can be assessed in its final position prior to release while maintaining the ability for the physician to reposition or fully resheath and retrieve the valve. The Lotus valve system also incorporates Adaptive Seal technology, designed to minimize aortic regurgitation.

"Combined with early and frequently complete elimination of aortic regurgitation as observed in REPRISE II, the unique features of the Lotus valve technology represent a significant step forward in the percutaneous treatment of eligible patients with severe symptomatic aortic stenosis," said Prof. Ian Meredith, AM, MBBS, PhD, Director of MonashHeart at Monash Medical Centre in Melbourne, Australia, and Principal Investigator of the REPRISE II trial.

Investigational device and not available for sale in the US. Indications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with each device. Information for use only in countries with applicable health authority product registrations.

Coherex WaveCrest LAA Occlusion System

Coherex Medical
(801) 433-9900
www.coherex.com

KEY FEATURES

- Retractable anchoring
- ePTFE material minimizes thrombus formation
- 20 points of anchoring
- Acute assessment through distal contrast injection
- Proximal positioning in the LAA

The Coherex WaveCrest left atrial appendage (LAA) occlusion system developed by Coherex Medical (Salt Lake City, UT) recently received CE Mark approval. The design of the WaveCrest system accommodates a wide range of LAA anatomies. The implant is built from ePTFE, which minimizes undesired thrombus formation on the outside of the occluder. Independent anchors stabilize the device after positioning. It has the most anchoring points of any available LAA occluder and has a distal injection port to assess position, stability, and closure during the implant procedure. Coherex has partnered with Biosense Webster (Diamond Bar, CA) as the exclusive distributor for WaveCrest.



Destino Twist Steerable Guiding Sheath

Oscor Inc.
(727) 937-2511
www.oscor.com

KEY FEATURES

- Unidirectional deflectable tip
- Ergonomic steerable handle
- Oscor SureSeal technology

Oscor Inc. (Palm Harbor, FL) announced the launch of the Destino Twist, a unidirectional steerable guiding sheath that has received US Food and Drug Administration clearance and CE Mark approval. The device has a unidirectional deflectable tip with an ergonomic steerable handle and comes in a wide variety of French sizes, curves, and lengths. Destino Twist is intended for gaining access in interventional and renal applications and incorporates Oscor SureSeal technology for reliable hemostasis.



Promus Premier Stent System

Boston Scientific Corporation
(888) 272-1001
www.bostonscientific.com/promuspremier-US

KEY FEATURES

- Customized PtCr stent architecture
- Market-leading everolimus drug elution
- Enhanced stent delivery system

Boston Scientific Corporation (Natick, MA) received CE Mark and US Food and Drug Administration approval for their next-generation durable-polymer drug-eluting stent technology—the Promus Premier stent system. It is the only drug-eluting stent to feature a customized platinum chromium (PtCr) stent architecture, the market-leading everolimus drug coating and fluorinated copolymer, and an enhanced stent delivery system.

The stent's unique PtCr architecture provides strength without compromising flexibility. Its enhanced, low-profile delivery system features a shorter, more visible tip; a dual-layer Pebax balloon; and a Bi-Segment inner lumen catheter to facilitate precise stent delivery across challenging lesions.

"After using Promus Premier for nearly a year, it is clear that Boston Scientific has advanced thin-strut technology," said John Ormiston, MD, of Mercy Angiography Auckland Hospital in Auckland, New Zealand. ■